FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203282393> ?p ?o ?g. }

• W3203282393 endingPage "100412" @default.
• W3203282393 startingPage "100412" @default.
• W3203282393 abstract "Mirabegron, a b3-adrenoceptor (b3-AR) agonist approved for the treatment of overactive bladder (OAB) symptoms in the adult population, is the first of a new class of compounds with a different mechanism of action. Mirabegron act during the bladder storage phase by relaxing the detrusor muscle thus increase bladder capacity without any significant impact on voiding. Although antimuscarinic agents are commonly used for daytime incontinence associated with overactive bladder and also for patient with congenital cause such as spina bifida, mirabegron could be an effective treatment option in children with neurogenic bladder, as shown in adult populations. In this systematic review, we aimed to evaluate the available literature regarding efficacy and safety of mirabegron in pediatric population. This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The symptoms analyzed were frequency, urgency, nocturnal enuresis (NE) and daytime incontinence (DI). 37 (53%) out of 70 children were still receiving treatment at 6 months; 30 received mirabegron monotherapy, and 7 received combination therapy with anticholinergic (Solifenacin n = 4, Desmopressin n = 2, both n = 1). After six months, blood pressure monitoring and ECGs were normal in all patients. For patients on monotherapy, 6 of 17 (35%) had improvement in NE, 11 of 19 (58%) in DI, 12 of 20 (60%) in frequency, and 8 of 21 (38%) in urgency symptoms. For patients receiving combination therapy, 2 of 6 (33%) had improvement in NE, 2 of 4 in DI (50%), 2 of 4 (50%) in frequency, and 4 of 6 (67%) had improvement in urgency. The CV safety of mirabegron, the only clinically available β 3 -adrenoceptor agonist, appears to be good and comparable with that of antimuscarinic agents, the current first-line therapy for OAB. However, Further long-term data are desirable especially in patients with poorly controlled hypertension, arrhythmia, or cardiac heart failure. • Mirabegron appears to be good and comparable with that of antimuscarinic agent. • Antimuscarinics decrease the activity of afferent nerve which inhibits acetylcholine released and bladder contractions. • Mirabegron is a novel ‘first in class’ medication with promising outcomes for OAB symptoms in adults." @default.
• W3203282393 created "2021-10-11" @default.
• W3203282393 creator A5025553577 @default.
• W3203282393 creator A5046223898 @default.
• W3203282393 creator A5073883523 @default.
• W3203282393 date "2021-09-01" @default.
• W3203282393 modified "2023-10-17" @default.
• W3203282393 title "Efficacy and Safety of Mirabegron in Pediatric Population: A Systematic Review" @default.
• W3203282393 cites W1632083014 @default.
• W3203282393 cites W1738560352 @default.
• W3203282393 cites W1787320721 @default.
• W3203282393 cites W1966043663 @default.
• W3203282393 cites W1978083855 @default.
• W3203282393 cites W1981218720 @default.
• W3203282393 cites W1987641034 @default.
• W3203282393 cites W1991167830 @default.
• W3203282393 cites W1998003688 @default.
• W3203282393 cites W2002896923 @default.
• W3203282393 cites W2005256857 @default.
• W3203282393 cites W2007886796 @default.
• W3203282393 cites W2018017258 @default.
• W3203282393 cites W2024557546 @default.
• W3203282393 cites W2033817897 @default.
• W3203282393 cites W2036978792 @default.
• W3203282393 cites W2051963332 @default.
• W3203282393 cites W2055316922 @default.
• W3203282393 cites W2059507502 @default.
• W3203282393 cites W2059735303 @default.
• W3203282393 cites W2067945145 @default.
• W3203282393 cites W2082897746 @default.
• W3203282393 cites W2095018779 @default.
• W3203282393 cites W2106826128 @default.
• W3203282393 cites W2107806473 @default.
• W3203282393 cites W2111359369 @default.
• W3203282393 cites W2120812596 @default.
• W3203282393 cites W2121960800 @default.
• W3203282393 cites W2128421946 @default.
• W3203282393 cites W2138057956 @default.
• W3203282393 cites W2142727765 @default.
• W3203282393 cites W2179853945 @default.
• W3203282393 cites W2261727231 @default.
• W3203282393 cites W2465275747 @default.
• W3203282393 cites W2559558704 @default.
• W3203282393 cites W2883546793 @default.
• W3203282393 cites W2902528338 @default.
• W3203282393 cites W2987313575 @default.
• W3203282393 cites W3146142859 @default.
• W3203282393 doi "https://doi.org/10.1016/j.ijso.2021.100412" @default.
• W3203282393 hasPublicationYear "2021" @default.
• W3203282393 type Work @default.
• W3203282393 sameAs 3203282393 @default.
• W3203282393 citedByCount "0" @default.
• W3203282393 crossrefType "journal-article" @default.
• W3203282393 hasAuthorship W3203282393A5025553577 @default.
• W3203282393 hasAuthorship W3203282393A5046223898 @default.
• W3203282393 hasAuthorship W3203282393A5073883523 @default.
• W3203282393 hasBestOaLocation W32032823931 @default.
• W3203282393 hasConcept C126322002 @default.
• W3203282393 hasConcept C126894567 @default.
• W3203282393 hasConcept C142724271 @default.
• W3203282393 hasConcept C204787440 @default.
• W3203282393 hasConcept C2777333188 @default.
• W3203282393 hasConcept C2777844464 @default.
• W3203282393 hasConcept C2777912814 @default.
• W3203282393 hasConcept C2778164427 @default.
• W3203282393 hasConcept C2778689640 @default.
• W3203282393 hasConcept C2778702241 @default.
• W3203282393 hasConcept C2778941218 @default.
• W3203282393 hasConcept C2779502394 @default.
• W3203282393 hasConcept C2780610425 @default.
• W3203282393 hasConcept C2781020410 @default.
• W3203282393 hasConcept C2908647359 @default.
• W3203282393 hasConcept C71924100 @default.
• W3203282393 hasConcept C77411442 @default.
• W3203282393 hasConcept C99454951 @default.
• W3203282393 hasConceptScore W3203282393C126322002 @default.
• W3203282393 hasConceptScore W3203282393C126894567 @default.
• W3203282393 hasConceptScore W3203282393C142724271 @default.
• W3203282393 hasConceptScore W3203282393C204787440 @default.
• W3203282393 hasConceptScore W3203282393C2777333188 @default.
• W3203282393 hasConceptScore W3203282393C2777844464 @default.
• W3203282393 hasConceptScore W3203282393C2777912814 @default.
• W3203282393 hasConceptScore W3203282393C2778164427 @default.
• W3203282393 hasConceptScore W3203282393C2778689640 @default.
• W3203282393 hasConceptScore W3203282393C2778702241 @default.
• W3203282393 hasConceptScore W3203282393C2778941218 @default.
• W3203282393 hasConceptScore W3203282393C2779502394 @default.
• W3203282393 hasConceptScore W3203282393C2780610425 @default.
• W3203282393 hasConceptScore W3203282393C2781020410 @default.
• W3203282393 hasConceptScore W3203282393C2908647359 @default.
• W3203282393 hasConceptScore W3203282393C71924100 @default.
• W3203282393 hasConceptScore W3203282393C77411442 @default.
• W3203282393 hasConceptScore W3203282393C99454951 @default.
• W3203282393 hasLocation W32032823931 @default.
• W3203282393 hasOpenAccess W3203282393 @default.
• W3203282393 hasPrimaryLocation W32032823931 @default.
• W3203282393 hasRelatedWork W10274833 @default.
• W3203282393 hasRelatedWork W13689 @default.

• next